Balyasny Asset Management LLC Crinetics Pharmaceuticals, Inc. Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 53,042 shares of CRNX stock, worth $2.84 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,042
Previous 114,637
53.73%
Holding current value
$2.84 Million
Previous $5.13 Million
47.23%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.5MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$337 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$334 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$315 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$265 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$239 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.88B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...